D'ALESSIO, Andrea
 Distribuzione geografica
Continente #
AS - Asia 664
EU - Europa 531
NA - Nord America 510
SA - Sud America 95
AF - Africa 51
OC - Oceania 3
Totale 1.854
Nazione #
US - Stati Uniti d'America 480
RU - Federazione Russa 255
SG - Singapore 230
HK - Hong Kong 140
CN - Cina 117
BR - Brasile 84
VN - Vietnam 70
IT - Italia 60
DE - Germania 50
FR - Francia 43
BJ - Benin 37
GB - Regno Unito 30
IN - India 23
KR - Corea 23
AT - Austria 17
JP - Giappone 14
CA - Canada 13
BD - Bangladesh 12
IE - Irlanda 12
MX - Messico 11
NL - Olanda 11
SE - Svezia 9
FI - Finlandia 8
PL - Polonia 8
UA - Ucraina 8
TR - Turchia 6
ES - Italia 5
PK - Pakistan 5
AR - Argentina 4
CO - Colombia 4
CZ - Repubblica Ceca 4
LT - Lituania 4
ZA - Sudafrica 4
AE - Emirati Arabi Uniti 3
EG - Egitto 3
IQ - Iraq 3
MA - Marocco 3
AU - Australia 2
BG - Bulgaria 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ID - Indonesia 2
IL - Israele 2
NP - Nepal 2
PS - Palestinian Territory 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
AZ - Azerbaigian 1
BE - Belgio 1
CR - Costa Rica 1
EC - Ecuador 1
GD - Grenada 1
JM - Giamaica 1
KZ - Kazakistan 1
LY - Libia 1
MY - Malesia 1
NR - Nauru 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
SI - Slovenia 1
SN - Senegal 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VE - Venezuela 1
Totale 1.854
Città #
Hong Kong 140
Singapore 121
San Jose 107
Ashburn 76
Beijing 38
Cotonou 37
Los Angeles 31
Moscow 27
Ho Chi Minh City 26
Lauterbourg 24
Seoul 22
Santa Clara 18
New York 17
Falkenstein 16
Hanoi 16
São Paulo 16
Nuremberg 13
Tokyo 13
Assago 12
Buffalo 12
Dublin 12
Denver 11
Chicago 10
Chennai 9
Frankfurt am Main 9
Stockholm 9
Vienna 9
Amsterdam 8
Brooklyn 8
Helsinki 8
London 7
Manchester 7
Mexico City 7
Orem 7
Warsaw 7
Ankara 6
Boardman 5
Boston 5
Da Nang 5
Poplar 5
Tianjin 5
Turin 5
Atlanta 4
Mezzomerico 4
Milan 4
Novara 4
Roubaix 4
Belo Horizonte 3
Hangzhou 3
Houston 3
Johannesburg 3
Montreal 3
Munich 3
Pardubice 3
Rome 3
Toronto 3
Uberlândia 3
Wuhan 3
Baghdad 2
Bexley 2
Cairo 2
Calimaya 2
Cleveland 2
Concord 2
Concórdia 2
Contagem 2
Council Bluffs 2
Dallas 2
Deiva Marina 2
Delhi 2
Florence 2
Haiphong 2
Hải Dương 2
Kathmandu 2
Louisville 2
Medellín 2
Mumbai 2
New Delhi 2
Paris 2
Phoenix 2
Recife 2
San Francisco 2
Santa Fe 2
Secaucus 2
Shanghai 2
Sydney 2
Tashkent 2
Uzzano 2
Valduggia 2
Vercelli 2
Zurich 2
Agrolândia 1
Algiers 1
Almaty 1
Anápolis 1
Apollo 1
Araxá 1
Açu 1
Bahadurgarh 1
Baku 1
Totale 1.074
Nome #
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 107
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 102
Effective and organ doses in patient undergoing interventional neuroradiology procedures: A multicentre study 90
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 83
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 82
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 79
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 76
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 75
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 72
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 72
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 71
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials 70
Cumulative radiation exposure from radiological imaging in patients with Hodgkin and diffuse large b-cell lymphoma not submitted to radiotherapy 70
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? 69
. Optimisation of protection in the medical exposure of recurrent adult patients due to computed tomography procedures: development of recurrent exposures reference levels. 67
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 65
Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial 64
Reply 63
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 62
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma 59
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 59
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma 59
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study 57
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 55
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 55
Dissecting the Tumor Microenvironment to Predict Immunotherapy Response in Hepatocellular Cancer 51
Reply 48
Totale 1.882
Categoria #
all - tutte 9.902
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.902


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024125 30 0 10 7 20 0 14 4 0 3 5 32
2024/2025490 6 2 46 4 5 66 58 41 76 79 32 75
2025/20261.267 61 51 69 166 210 123 205 200 107 75 0 0
Totale 1.882